Amylyx Pharmaceuticals, Inc. (AMLX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Amylyx is a clinical-stage pharmaceutical company focused on developing novel therapies for endocrine conditions and neurodegenerative diseases. The company currently has no approved commercial products following the voluntary discontinuation of RELYVRIO/ALBRIOZA in 2024. Its pipeline includes avexitide (for post-bariatric hypoglycemia), AMX0035 (for Wolfram syndrome), and AMX0114 (for ALS).
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Product Revenue | $0 | $0.4M | $0 | $88.0M |
| Net Loss | $(34.4M) | $(72.7M) | $(111.7M) | $(264.2M) |
| Diluted EPS | $(0.37) | $(1.07) | $(1.25) | $(3.89) |
| Operating Expenses | $36.0M | $76.1M | $116.7M | $362.1M |
| Cash & Equivalents | $225.2M | $77.4M | $225.2M | $77.4M |
| Marketable Securities | $118.8M | $99.1M | $118.8M | $99.1M |
| Total Liquidity | $344.0M | $176.5M | $344.0M | $176.5M |
Note: The company reported no revenue for the current period. Operating expenses decreased significantly year-over-year due to the absence of inventory impairment charges and restructuring costs incurred in 2024.
Material Changes vs. Prior Period
- Revenue Elimination: Product revenue dropped to zero as the company ceased sales of RELYVRIO/ALBRIOZA. In contrast, Q3 2024 included $0.4M in revenue, and YTD 2024 included $88.0M.
- Expense Reduction: Total operating expenses decreased by 53% in Q3 2025 compared to Q3 2024. This is primarily due to the absence of a $36.2M charge for acquired in-process research and development (IPR&D) and $0.8M in inventory impairment recorded in Q3 2024.
- Capital Raise: The company significantly strengthened its balance sheet through two equity offerings in 2025:
- January 2025: Raised ~$65.5M net.
- September 2025: Raised ~$190.7M net.
- Cash Position: Total cash, cash equivalents, and marketable securities increased from $176.5M at year-end 2024 to $344.0M at September 30, 2025.
Guidance, Outlook, and Risks
- Clinical Progress:
- Avexitide (PBH): The pivotal Phase 3 LUCIDITY trial is ongoing. Recruitment is expected to complete in Q1 2026, with topline data anticipated in Q3 2026. Commercial launch is targeted for 2027 if approved.
- AMX0035 (Wolfram Syndrome): Positive long-term data (Week 48) from the Phase 2 HELIOS trial was announced. A pivotal Phase 3 trial is planned for initiation in H2 2026.
- AMX0114 (ALS): The Phase 1 LUMINA trial is ongoing; Cohort 1 was fully enrolled in September 2025.
- Discontinuation: The ORION program for AMX0035 in Progressive Supranuclear Palsy (PSP) was discontinued in August 2025 due to lack of efficacy.
- Liquidity Outlook: Management believes current cash resources ($344.0M) are sufficient to fund operations into 2028.
- Legal Proceedings: The company is defending against a putative class action lawsuit (Shih v. Amylyx) regarding statements made about RELYVRIO. The court denied the motion to dismiss in September 2025. Two derivative complaints are also pending but currently stayed.
- Risk Factors: Key risks include the failure of clinical trials, inability to secure regulatory approval, dependence on third-party manufacturers, and the need for additional capital if the current runway is exhausted sooner than expected.
Investor Verification Checklist
- Verify the enrollment status and timeline for the LUCIDITY Phase 3 trial for avexitide, as this is the primary near-term catalyst.
- Monitor the status of the Shih v. Amylyx securities litigation and any potential settlement impacts.
- Confirm the company's burn rate and cash runway projections against the stated 2028 timeline, given the high cost of Phase 3 trials.
- Review the FDA's response to the IND application for AMX0114 and the timeline for biomarker data release.
- Assess the impact of the discontinued PSP program on the overall R&D budget and resource allocation for Wolfram syndrome.